Hepatitis C treatment with direct antiviral agents induce mild renal impairment

Bravo, Michelle; Capel, Tiago Leoni; González, Patricia; Gagliardi, Lucilla; Barranco, R.; Chico, Inmaculada; Rodríguez, R.; Delgado, M.

doi:10.1016/s0168-8278(17)31926-8

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…50 However, some controversy still exists highlighted by a recent report of 90 patients treated with PROD and SOFbased therapies. 51 A 10% increase in serum creatinine values was observed 24 weeks following the end of treatment (P < 0.0001). Worsening of kidney function occurred mainly during the first 4 weeks of treatment, and then stabilized, but did not return to baseline values after cessation of therapy.…”

Section: Risk Of Kidney Injury With Daasmentioning

confidence: 89%

“…The type of DAA combination used did not influence the renal impairment seen, nor did the use of RBV. 51 In the electronically retrieved cohort of HCV infected veterans (ERCHIVES) cohort, the impact of DAAs on eGFR was evaluated retrospectively. 52 In 3899 patients treated with SOF/LDV 6 RBV, a >10 mL/min/1.73 m 2 decline in eGFR was observed in 27% of those with baseline eGFR of 60 mL/min/1.73 m 2 , 21.2% of those with baseline eGFR of 30-59 mL/min/1.73 m 2 , and 7.7% of those with baseline eGFR of <30 mL/min/1.73 m 2 (P 5 0.01).…”

Section: Risk Of Kidney Injury With Daasmentioning

confidence: 99%

See 1 more Smart Citation

Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease

Ridruejo

Mendizábal

Silva

2018

Hemodialysis International

View full text Add to dashboard Cite

Hepatitis C virus infection (HCV) is highly prevalent in patients with chronic kidney disease (CKD) and kidney transplant recipients. Little information exists on treatment in patients with CKD stages 2 to 3, where CKD progression might be slowed by HCV treatment. These patients are not considered a high priority for HCV treatment in most international guidelines. Although some recently published guidelines propose universal treatment, others are still recommending it only in high priority groups. In this review, we evaluate current evidence of HCV infection impact on CKD progression, on cardiovascular and metabolic risk, and the benefits of HCV infection treatment to improve cardiovascular and metabolic outcomes. We made special focus on the benefits of HCV infection treatment in patients with stages 2 to 3 CKD to avoid CKD progression.

show abstract

Section: Risk Of Kidney Injury With Daasmentioning

confidence: 89%

Section: Risk Of Kidney Injury With Daasmentioning

confidence: 99%